Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
To develop a radiomics model with all-relevant imaging features from multiphasic computed tomography (CT) for differentiating clear cell renal cell carcinoma (ccRCC) from non-ccRCC and to investigate the possible radiogenomics link between the imaging features and a key ccRCC driver gene-the von Hippel-Lindau (VHL) gene mutation.
|
30523454 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The last 30 years of research in renal cell carcinoma (RCC) has revealed that the vast majority of RCC histologies share a recurrent pattern of mutations to metabolic genes, including VHL, MTOR, ELOC, TSC1/2, FH, SDH, and mitochondrial DNA.
|
31155438 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Previously we have described that RWDD3 or RSUME (RWD domain-containing protein SUMO Enhancer) sumoylates and binds VHL protein and negatively regulates HIF degradation, leading to xenograft RCC tumor growth in mice.
|
30890701 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The evolution patterns of ccRCC have great inter-patient heterogeneities, with del(3p) being regarded as the common earliest event followed by three early departure points: VHL and PBRM1 mutations, del(14q) and other somatic copy number alterations (SCNAs) including amp(7), del(1p) and del(6q).
|
30886153 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Taken together, the findings of this study suggest that the protein levels of HIF2A and VEGFA in tumor tissue may serve as independent prognostic factors in ccRCC. ccRCC patients with increased intratumoral HIF2A and VEGFA protein levels, and unaltered VHL protein levels, are not likely to benefit from sunitinib treatment following nephrectomy; however, this hypothesis requires verification by large‑scale replication studies.
|
31268155 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
As an application of this resource, we discovered RCC GCN edges and modules that were associated with genetic lesions in known RCC driver genes, including VHL, a common initiating clear cell RCC (ccRCC) genetic lesion, and PBRM1 and BAP1 which are early genetic lesions in the Braided Cancer River Model (BCRM).
|
30814637 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
For an early diagnosis of VHL, before the occurrence of cancers (especially renal cell carcinoma), it is of huge importance to initiate VHL genetic testing in at-risk patients.
|
29764331 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In the Oncomine database, FBXO11 mRNA levels were lower in normal tissues than in cancer tissues, including clear cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (pRCC), hereditary ccRCC, non-hereditary ccRCC, VHL mutant ccRCC and VHL wild-type ccRCC.
|
31159774 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
In addition, SUMOylation of MITF modulates renal tumors secondary to melanoma, Similarly, SUMOylation of tumor suppressor gene VHL regulates the occurrence of renal cell carcinoma in VHL syndrome.
|
30707172 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
HIFs contribute to the pathogenesis of many cancers, particularly the clear cell type of renal cell carcinoma in which loss of function of the von Hippel-Lindau tumor suppressor blocks HIF-2α degradation.
|
30625281 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Steroid SULT gene-upregulated ccRCC cases showed mutual exclusivity with mutations of VHL, SETD2 and PBRM1, and with focal deletions of 3p and 9p, respectively.
|
31655797 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
KLF6 expression is driven by a robust super enhancer that integrates signals from multiple pathways, including the ccRCC-initiating VHL-HIF2A pathway.
|
30858363 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
VHL status regulates transforming growth factor-β signaling pathways in renal cell carcinoma.
|
29662646 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Additionally, a new similarity-based multi-objective optimization algorithm (SMO) was developed for training the MCMO to predict ccRCC related gene mutations (VHL, PBRM1 and BAP1) using quantitative CT features.
|
30277889 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
CLEC3B genetic deletion was coupled with the well‑known genetic loss of the von Hippel‑Lindau tumor suppressor, which is a characteristic oncogenic event during ccRCC carcinogenesis.
|
30066941 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
VHL mutations were detected in 26/55 (47%) RCC patients.
|
30514329 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Clear-cell renal-cell carcinoma (ccRCC) is characterized by loss of a functional Von Hippel-Lindau (VHL) protein.
|
29503246 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
VHL protein (pVHL) expression was evaluated by immunoblotting in the human RCC cell lines CAKI, ACHN, 786‑O, 769‑P and A498.
|
29845253 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
VHL is a major tumour suppressor in ccRCC and loss of VHL leads to stabilisation of hypoxia inducible factors HIF-1α and HIF-2α.
|
29872221 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
This could assist in identifying patients who need early aggressive management and deepen our understanding of the pathogenesis of VHL-WT ccRCC.
|
29239102 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
In previous studies, we found that 2'-hydroxyflavonone (2HF), a citrus flavonoid, inhibits the growth of renal cell carcinoma in a VHL-dependent manner.
|
30546837 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
PosttranslationalModification
|
disease |
BEFREE |
Because 3p loss and VHL inactivation are nearly universal truncal events in ccRCC, the resulting HIF1/2 signaling overdrive and accompanied tumor hypervascularization probably underlie the therapeutic benefits observed with vascular endothelial growth factor receptor inhibitors, including sorafenib, sunitinib, pazopanib, axitinib, bevacizumab, cabozantinib, and lenvatinib.
|
30372397 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The majority of ccRCC tumors are characterized by the loss of Von Hippel⁻Lindau tumor suppressor gene function, a stable expression of hypoxia-inducible factors 1α and 2α (HIFs), an altered expression of tumor-specific oncogenic microRNAs (miRNAs), a clear cytoplasm with dense lipid content, and overexpression of thymidine phosphorylase.
|
30380599 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Renal cell carcinoma (RCC) is highly dependent on angiogenesis, due to the overactivation of the VHL/HIF/VEGF/VEGFRs axis; this justifies the marked sensitivity of this neoplasm to antiangiogenic agents which, however, ultimately fail to control tumor growth.
|
30447930 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these results demonstrate that dsVHL-821, a novel saRNA for VHL, induces the expression of the VHL gene by epigenetic changes, leading to inhibition of cell growth and induction of apoptosis, and suggest that targeted activation of VHL by dsVHL-821 may be explored as a novel treatment of renal cell carcinoma.
|
29425832 |
2018 |